Development of an inhibiting antibody against equine interleukin 5 to treat insect bite hypersensitivity of horses

Autor: Nora Langreder, Dorina Schäckermann, Doris Meier, Marlies Becker, Maren Schubert, Stefan Dübel, Thomas Reinard, Stefanie Figge-Wegener, Kristine Roßbach, Wolfgang Bäumer, Simone Ladel, Michael Hust

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)

Abstract Insect bite hypersensitivity (IBH) is the most common allergic skin disease of horses. It is caused by insect bites of the Culicoides spp. which mediate a type I/IVb allergy with strong involvement of eosinophil cells. No specific treatment

Externí odkaz: https://doaj.org/article/6ff4edd772434189b50b3655420751c3

Baculovirus-free insect cell expression system for high yield antibody and antigen production

Autor: Janin Korn, Dorina Schäckermann, Toni Kirmann, Federico Bertoglio, Stephan Steinke, Janyn Heisig, Maximilian Ruschig, Gertrudis Rojas, Nora Langreder, Esther Veronika Wenzel, Kristian Daniel Ralph Roth, Marlies Becker, Doris Meier, Joop van den Heuvel, Michael Hust, Stefan Dübel, Maren Schubert

Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)

Abstract Antibodies are essential tools for therapy and diagnostics. Yet, production remains expensive as it is mostly done in mammalian expression systems. As most therapeutic IgG require mammalian glycosylation to interact with the human immune sys

Externí odkaz: https://doaj.org/article/58d50e96dc5f45bcb3f271b3937cc6e0

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Autor: Federico Bertoglio, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Leila Abassi, Thomas Klünemann, Ulfert Rand, Doris Meier, Nora Langreder, Stephan Steinke, Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth, Philipp Kuhn, Peggy Riese, Dorina Schäckermann, Janin Korn, Allan Koch, M. Zeeshan Chaudhry, Kathrin Eschke, Yeonsu Kim, Susanne Zock-Emmenthal, Marlies Becker, Margitta Scholz, Gustavo Marçal Schmidt Garcia Moreira, Esther Veronika Wenzel, Giulio Russo, Hendrikus S.P. Garritsen, Sebastian Casu, Andreas Gerstner, Günter Roth, Julia Adler, Jakob Trimpert, Andreas Hermann, Thomas Schirrmann, Stefan Dübel, André Frenzel, Joop Van den Heuvel, Luka Čičin-Šain, Maren Schubert, Michael Hust

Publikováno v: Cell Reports, Vol 36, Iss 4, Pp 109433- (2021)

Summary: The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody g

Externí odkaz: https://doaj.org/article/9c2876f60a3849cc9e53afa0c2d3362e

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

Autor: Sebastian Casu, Federico Bertoglio, Kristian Daniel Ralph Roth, Maren Schubert, Peggy Riese, Stephan Steinke, André Frenzel, Yeonsu Kim, Margitta Scholz, Michael Hust, Hendrikus S.P. Garritsen, Allan Koch, Thomas Schirrmann, Maximilian Ruschig, Rico Ballmann, Stefan Dübel, Günter Roth, Dorina Schäckermann, Giulio Russo, Ulfert Rand, Thomas Klünemann, Marlies Becker, Gustavo Marçal Schmidt Garcia Moreira, Philipp Kuhn, Janin Korn, Philip Alexander Heine, Doris Meier, Luka Cicin-Sain, Nora Langreder, Esther Veronika Wenzel, Kathrin Eschke, Andreas Gerstner, Viola Fühner, Julia Adler, Andreas Hermann, Susanne Zock-Emmenthal, Leila Abasi, Joop van den Heuvel, Jakob Trimpert, Kai-Thomas Schneider, M. Zeeshan Chaudhry

The novel betacoranavirus SARS-CoV-2 causes a form of severe pneumonia disease, termed COVID-19 (coronavirus disease 2019). Recombinant human antibodies are proven potent neutralizers of viruses and can block the interaction of viral surface proteins

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d0ea4e53163c64198aa669c61357674
https://doi.org/10.1101/2020.12.03.409318

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Autor: Andreas Gerstner, Philipp Kuhn, Kathrin Eschke, Sebastian Casu, Gustavo Marçal Schmidt Garcia Moreira, Viola Fühner, Yeonsu Kim, Jakob Trimpert, Giulio Russo, Margitta Scholz, Michael Hust, Doris Meier, Maximilian Ruschig, Nora Langreder, Kai-Thomas Schneider, Julia Adler, Rico Ballmann, Luka Cicin-Sain, Ulfert Rand, Thomas Schirrmann, Dorina Schäckermann, Andreas Hermann, Federico Bertoglio, Joop van den Heuvel, Janin Korn, M. Zeeshan Chaudhry, Maren Schubert, Peggy Riese, Allan Koch, André Frenzel, Stephan Steinke, Leila Abassi, Kristian Daniel Ralph Roth, Susanne Zock-Emmenthal, Hendrikus S.P. Garritsen, Thomas Klünemann, Stefan Dübel, Marlies Becker, Esther Veronika Wenzel, Philip Alexander Heine, Günter Roth

Publikováno v: Cell reports 36(4), 109433 (2021). doi:10.1016/j.celrep.2021.109433
Cell Report
Cell reports, Volume 36, ISSUE 4, 109433, July 27, 2021--Cell Rep--http://cellreports.cell.com/--http://www.sciencedirect.com/science/journal/22111247--http://www.bibliothek.uni-regensburg.de/ezeit/?2649101--2211-1247--2211-1247
Cell Reports
Cell reports
United States
Cell Reports, Vol 36, Iss 4, Pp 109433-(2021)

Cell reports 36(4), 109433 (2021). doi:10.1016/j.celrep.2021.109433
The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45d0f3e6cf1ebd5cd4dc9d1bf21889b